These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 24291104)

  • 21. Discovery of [1,2,4]triazolo[4,3-a]pyridines as potent Smoothened inhibitors targeting the Hedgehog pathway with improved antitumor activity in vivo.
    Tian N; Wu H; Zhang H; Yang D; Lv L; Yang Z; Zhang T; Quan D; Zhou L; Xie Y; Xu Y; Wei N; Zhang J; Chen M; Schmitz JC; Tian Y; Wu S
    Bioorg Med Chem; 2020 Aug; 28(16):115584. PubMed ID: 32690258
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting the hedgehog pathway to treat basal cell carcinoma.
    Geeraert P; Williams JS; Brownell I
    J Drugs Dermatol; 2013 May; 12(5):519-23. PubMed ID: 23652945
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of Hedgehog-dependent tumors and cancer stem cells by a newly identified naturally occurring chemotype.
    Infante P; Alfonsi R; Ingallina C; Quaglio D; Ghirga F; D'Acquarica I; Bernardi F; Di Magno L; Canettieri G; Screpanti I; Gulino A; Botta B; Mori M; Di Marcotullio L
    Cell Death Dis; 2016 Sep; 7(9):e2376. PubMed ID: 27899820
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Locally advanced and metastatic basal cell carcinoma: molecular pathways, treatment options and new targeted therapies.
    Ruiz Salas V; Alegre M; Garcés JR; Puig L
    Expert Rev Anticancer Ther; 2014 Jun; 14(6):741-9. PubMed ID: 24611655
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An Investigator-Initiated Open-Label Trial of Sonidegib in Advanced Basal Cell Carcinoma Patients Resistant to Vismodegib.
    Danial C; Sarin KY; Oro AE; Chang AL
    Clin Cancer Res; 2016 Mar; 22(6):1325-9. PubMed ID: 26546616
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery of the investigational drug TAK-441, a pyrrolo[3,2-c]pyridine derivative, as a highly potent and orally active hedgehog signaling inhibitor: modification of the core skeleton for improved solubility.
    Ohashi T; Oguro Y; Tanaka T; Shiokawa Z; Tanaka Y; Shibata S; Sato Y; Yamakawa H; Hattori H; Yamamoto Y; Kondo S; Miyamoto M; Nishihara M; Ishimura Y; Tojo H; Baba A; Sasaki S
    Bioorg Med Chem; 2012 Sep; 20(18):5507-17. PubMed ID: 22898254
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel hedgehog inhibitor for the treatment of hematological malignancies.
    Lin P; He Y; Chen G; Ma H; Zheng J; Zhang Z; Cao B; Zhang H; Zhang X; Mao X
    Anticancer Drugs; 2018 Nov; 29(10):995-1003. PubMed ID: 30106753
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hedgehog fights back: mechanisms of acquired resistance against Smoothened antagonists.
    Metcalfe C; de Sauvage FJ
    Cancer Res; 2011 Aug; 71(15):5057-61. PubMed ID: 21771911
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery of a potent hedgehog pathway inhibitor capable of activating caspase8-dependent apoptosis.
    Chen Q; Zhang H; Wu M; Wang Q; Luo L; Ma H; Zhang X; He S
    J Pharmacol Sci; 2018 Jul; 137(3):256-264. PubMed ID: 30064819
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glucocorticoid compounds modify smoothened localization and hedgehog pathway activity.
    Wang Y; Davidow L; Arvanites AC; Blanchard J; Lam K; Xu K; Oza V; Yoo JW; Ng JM; Curran T; Rubin LL; McMahon AP
    Chem Biol; 2012 Aug; 19(8):972-82. PubMed ID: 22921064
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hedgehog- and mTOR-targeted therapies for advanced basal cell carcinomas.
    Piérard-Franchimont C; Hermanns-Lê T; Paquet P; Herfs M; Delvenne P; Piérard GE
    Future Oncol; 2015 Nov; 11(22):2997-3002. PubMed ID: 26437034
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I and phase II sonidegib and vismodegib clinical trials for the treatment of paediatric and adult MB patients: a systemic review and meta-analysis.
    Li Y; Song Q; Day BW
    Acta Neuropathol Commun; 2019 Jul; 7(1):123. PubMed ID: 31362788
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetic and pharmacodynamic modeling of hedgehog inhibitor TAK-441 for the inhibition of Gli1 messenger RNA expression and antitumor efficacy in xenografted tumor model mice.
    Kogame A; Tagawa Y; Shibata S; Tojo H; Miyamoto M; Tohyama K; Kondo T; Prakash S; Shyu WC; Asahi S
    Drug Metab Dispos; 2013 Apr; 41(4):727-34. PubMed ID: 23298863
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Small Molecule Inhibitors of the Hedgehog Pathway in the Treatment of Basal Cell Carcinoma of the Skin.
    Danhof R; Lewis K; Brown M
    Am J Clin Dermatol; 2018 Apr; 19(2):195-207. PubMed ID: 28887802
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery of potent and novel smoothened antagonists via structure-based virtual screening and biological assays.
    Lu W; Zhang D; Ma H; Tian S; Zheng J; Wang Q; Luo L; Zhang X
    Eur J Med Chem; 2018 Jul; 155():34-48. PubMed ID: 29857275
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A sterol analog inhibits hedgehog pathway by blocking cholesterylation of smoothened.
    Liu YB; He LM; Sun M; Luo WJ; Lin ZC; Qiu ZP; Zhang YL; Hu A; Luo J; Qiu WW; Song BL
    Cell Chem Biol; 2024 Jul; 31(7):1264-1276.e7. PubMed ID: 38442710
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A novel indole derivative, 2-{3-[1-(benzylsulfonyl)piperidin-4-yl]-2-methyl-1H-indol-1-yl}-1-(pyrrolidin-1-yl)ethenone, suppresses hedgehog signaling and drug-resistant tumor growth.
    Jung JH; Lee H; Jeon J; Lee YJ; Nada H; Kim M; Lee H; Bhattarai D; Lee K; Ko HW
    Arch Pharm (Weinheim); 2024 Oct; 357(10):e2400218. PubMed ID: 38963677
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Small-molecule modulators of the Sonic Hedgehog signaling pathway.
    Stanton BZ; Peng LF
    Mol Biosyst; 2010 Jan; 6(1):44-54. PubMed ID: 20024066
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of a novel Smoothened antagonist that potently suppresses Hedgehog signaling.
    Wang J; Mook RA; Lu J; Gooden DM; Ribeiro A; Guo A; Barak LS; Lyerly HK; Chen W
    Bioorg Med Chem; 2012 Nov; 20(22):6751-7. PubMed ID: 23063522
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma.
    Sharpe HJ; Pau G; Dijkgraaf GJ; Basset-Seguin N; Modrusan Z; Januario T; Tsui V; Durham AB; Dlugosz AA; Haverty PM; Bourgon R; Tang JY; Sarin KY; Dirix L; Fisher DC; Rudin CM; Sofen H; Migden MR; Yauch RL; de Sauvage FJ
    Cancer Cell; 2015 Mar; 27(3):327-41. PubMed ID: 25759019
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.